XENE Q1 2024 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$599,000

Operating Income

-$59M

Net Income

-$48M

EPS (Diluted)

$-0.62

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$46M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$919M

Total Liabilities

$31M

Stockholders' Equity

$888M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$599,000	$0	—
Operating Income	-$59M	-$49M	-20.4%
Net Income	-$48M	-$42M	-14.9%